RXST

RxSight, Inc. (RXST) | Rumor.io

RxSight

RXST

Attention (50-day avg)0%

Attention rank (50-day avg)#3,976

Bullish sentiment (50-day avg)100%

Price to earnings ratio-4.92

Market capitalization194.2M

Earnings per share-1.14

Dividend yield (TTM)—

Revenue (annual)134.5M

Net income (annual)-38.9M

Social

What share of all stock conversation is about RXST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jul 10

$RXST has been down 77% since the beginning of the year and the author has exited the position.
The author likes $RXST for a potential trade, citing volume and a setup above the Volume-Weighted Average Price (VWAP).
Analysts have lowered their price targets for $RXST, with Piper Sandler lowering its target to $10, Wells Fargo to $9, Bank of America to $9, and Stifel to $9.

Generated by AI

Sentiment

Of the messages about RXST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	77.27% +24.91
Bearish	—	—	—	22.73% -24.91

Bullish· Jul 9

RxSight, Inc. has a strong balance sheet with $227.5 million in cash and cash equivalents, making it undervalued at its current market price.
The company's current market capitalization of $296 million is significantly lower than its potential value, suggesting a rebound to $9 or more in the near term.
A takeover offer from a company like Alcon, which has recently acquired Lensar and has $1B in cash, could be a possible outcome, making RxSight's current price an attractive entry point.

Bearish· Jul 9

The company's Q2 preliminary earnings were disastrous, cutting FY25 revenue guidance by 25% from $160M to $120M.
The stock's market capitalization has dropped by almost 200M, with the company's valuation now primarily driven by its cash reserves, valuing the technology at around $100M.
The stock has experienced a significant decline of over 40% in a short period, with some investors considering the drop to be a little overdone and potentially triggering a sharp recovery soon.

Generated by AI

Topics

Of the messages about RXST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	14.71%
Announcements	—	—	—	31.37%
Analysts	—	—	—	28.43%
Controversies	—	—	—	0%
Earnings	—	—	—	25.49%
Macro	—	—	—	0%

Community

Of the messages about RXST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	21.82%
Newcomers	—	100%	100%	78.18%

Jul 9

New investors are expressing concern over RxSight's recent poor performance, with a 33% drop in stock value after releasing disappointing Q2 preliminary earnings.
The company's market cap has decreased significantly, with some investors questioning the valuation of the company's technology, currently estimated at around $100 million.
The stock's decline has led to a decrease in investor confidence, with some considering the possibility of a total collapse risk, similar to what has been seen in companies with high growth rates slowing down.

Generated by AI

News

RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says

RxSight (RXST) has upside potential if it executes salesforce expansion and utilization-growth initi

6d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP)

Detailed price information for Rxsight Inc (RXST-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

BofA Adjusts Price Target on RxSight to $5.50 From $6.50

RxSight (RXST) has an average rating of hold and mean price target of $7.57, according to analysts p

8d agoYahoo Finance

Also Discussed

Investors talking about RXST also mention

#	Name	Attention
1	Abivax SAABVX	0.01%-0.01
2	STAAR Surgical CompanySTAA	0%new
3	Alcon Inc.ALC	0%0
4	Doximity Inc. Class A Common StockDOCS	0%0
5	America's Car-Mart, Inc.CRMT	0%0
6	Zenas BioPharma, Inc.ZBIO	0%0
7	ALX Oncology Holdings Inc.ALXO	0%0
8	Ultragenyx Pharmaceutical Inc.RARE	0.01%+0.01
9	Elicio Therapeutics Inc.ELTX	0%0
10	Pagaya Technologies Ltd. Class A Ordinary SharesPGY	0%+0

RxSight, Inc.

Healthcare
Medical Devices

RxSight, Inc. is a commercial-stage ophthalmic medical technology company focused on improving vision outcomes after cataract surgery. The company’s core offering is the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens and the Light Delivery Device, along with related accessories used by eye care professionals. This platform allows doctors to customize and optimize a patient’s visual acuity after implantation, addressing a major need in premium cataract care. RxSight serves ophthalmic surgeons, ambulatory surgery centers, and ophthalmology practices, with its products used in the U.S. cataract surgery market and selected international markets through distribution partners. Headquartered in Aliso Viejo, California, RxSight operates as a specialized medical device business centered on adjustable intraocular lens technology and post-surgical vision refinement.

Website

Location

100 Columbia

Aliso Viejo, CA, 92656

United States

Social

What share of all stock conversation is about RXST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jul 10

$RXST has been down 77% since the beginning of the year and the author has exited the position.
The author likes $RXST for a potential trade, citing volume and a setup above the Volume-Weighted Average Price (VWAP).
Analysts have lowered their price targets for $RXST, with Piper Sandler lowering its target to $10, Wells Fargo to $9, Bank of America to $9, and Stifel to $9.

Generated by AI

Sentiment

Of the messages about RXST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	77.27% +24.91
Bearish	—	—	—	22.73% -24.91

Bullish· Jul 9

RxSight, Inc. has a strong balance sheet with $227.5 million in cash and cash equivalents, making it undervalued at its current market price.
The company's current market capitalization of $296 million is significantly lower than its potential value, suggesting a rebound to $9 or more in the near term.
A takeover offer from a company like Alcon, which has recently acquired Lensar and has $1B in cash, could be a possible outcome, making RxSight's current price an attractive entry point.

Bearish· Jul 9

The company's Q2 preliminary earnings were disastrous, cutting FY25 revenue guidance by 25% from $160M to $120M.
The stock's market capitalization has dropped by almost 200M, with the company's valuation now primarily driven by its cash reserves, valuing the technology at around $100M.
The stock has experienced a significant decline of over 40% in a short period, with some investors considering the drop to be a little overdone and potentially triggering a sharp recovery soon.

Generated by AI

Topics

Of the messages about RXST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	14.71%
Announcements	—	—	—	31.37%
Analysts	—	—	—	28.43%
Controversies	—	—	—	0%
Earnings	—	—	—	25.49%
Macro	—	—	—	0%

Community

Of the messages about RXST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	21.82%
Newcomers	—	100%	100%	78.18%

Jul 9

New investors are expressing concern over RxSight's recent poor performance, with a 33% drop in stock value after releasing disappointing Q2 preliminary earnings.
The company's market cap has decreased significantly, with some investors questioning the valuation of the company's technology, currently estimated at around $100 million.
The stock's decline has led to a decrease in investor confidence, with some considering the possibility of a total collapse risk, similar to what has been seen in companies with high growth rates slowing down.

Generated by AI

RxSight

Social

Jul 10

Bullish· Jul 9

Bearish· Jul 9

Jul 9

RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says

Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP)

BofA Adjusts Price Target on RxSight to $5.50 From $6.50

RxSight at wells fargo healthcare conference: reset centers on LAL growth

RxSight CFO Mark Wilterding sells $54,044 in company stock

RxSight COO Ilya Goldshleger sells $14,205 in company stock

Also Discussed

RxSight, Inc.

Company Information

Location

RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says

Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP)

BofA Adjusts Price Target on RxSight to $5.50 From $6.50

RxSight at wells fargo healthcare conference: reset centers on LAL growth

RxSight CFO Mark Wilterding sells $54,044 in company stock

RxSight COO Ilya Goldshleger sells $14,205 in company stock

Also Discussed

Social

Jul 10

Bullish· Jul 9

Bearish· Jul 9

Jul 9